Schistosomiasis, the second major parasitic disease in the world after malaria affects at least
200 million people, 500 million being exposed to the risk of infection. It is widely agreed that …

Schistosomiasis, the second major parasitic disease in the world after malaria, affects 200
million people. Vaccine strategies represent an essential component of the control of this …

Schistosomiasis is a chronic and debilitating parasitic disease that affects over 200 million
people throughout the world and causes about 500,000 deaths annually. Two specific …

Two specific characteristics of schistosome infection are of primordial importance to the
development of a vaccine: schistosomes do not multiply within the tissues of their definitive …

During the last 2 decades, much was learned concerning the nature of acquired immunity in
schistosomiasis, under experimental as well as field conditions. The knowledge is being …

The elucidation of the life cycle of the three major human schistosomes in Japan and Egypt
from 1910-1920 (Jordan & Webbe, 1982; Jordan, 1985) has made it possible to identify the …

For the development of vaccine strategies to generate efficient protection against chronic
infections such as parasitic diseases, and more precisely schistosomiasis, controlling …

The radiation-attenuated schistosome vaccine induces a high level of protective immunity in
rodents. In order to assess its potential relevance to man, we have tested its efficacy in the …

Mounting evidence for acquired immunity to schistosomiasis in humans supports the case
for immunological intervention. On the other hand, rapid reinfection poses a threat to …

Vaccination against human schistosomes in laboratory hosts is now a reality. A number of
different parasite molecules have been shown to confer partial protective immunity against …